SEARCH

SEARCH BY CITATION

References

  • 1
    Waly Raphael S, Yangde Z, YuXiang C. Hepatocellular carcinoma: focus on different aspects of management. ISRN Oncol 2012;2012:112.
  • 2
    Imai N, Kinoshita A, Onoda H, Iwaku A, Oishi M, Tanaka K, et al. Persistent elevated C-reactive protein after treatment is an independent marker of a poor prognosis in patients with hepatocellular carcinoma. Clin Transl Oncol 2012; 17.
  • 3
    El-Serag HB, Marrero JA, Rudolph L, Reddy KR. Diagnosis and treatment of hepatocellular carcinoma. Gastroenterology 2008;134:17521763.
  • 4
    Castanotto D, Rossi JJ. The promises and pitfalls of RNA-interference-based therapeutics. Nature 2009;457:426433.
  • 5
    Li L-C, Okino ST, Zhao H, Pookot D, Place RF, Urakami S, et al. Small dsRNAs induce transcriptional activation in human cells. Proc Natl Acad Sci U S A 2006;103:1733717342.
  • 6
    Janowski BA, Younger ST, Hardy DB, Ram R, Huffman KE, Corey DL. Activating gene expression in mammalian cells with promoter-targeted duplex RNAs. Nat Chem Biol 2007;3:166173.
  • 7
    Voutila J, et al. Gene expression profile changes after short-activating RNA-mediated induction of endogenous pluripotency factors in human mesenchymal stem cells. Mol Ther Nucleic Acids 2012;1:e35.
  • 8
    Hu JJ, Chen Z, Xia D, Wu J, Xu H, Ye Z-Q. Promoter-associated small double-stranded RNA interacts with heterogeneous nuclear ribonucleoprotein A2/B1 to induce transcriptional activation. Biochem J 2012;447:407416.
  • 9
    Kosaka M, Kang MR, Yang G, Li L-C. Targeted p21WAF1/CIP1 activation by RNAa inhibits hepatocellular carcinoma cells. Nucleic Acid Ther 2012;22:335343.
  • 10
    Place RF, Wang J, Noonan EJ, Meyers R, Manoharan M, Charisse K, et al. Formulation of small activating RNA into lipidoid nanoparticles inhibits xenograft prostate tumor growth by inducing p21 expression. Mol Ther Nucleic Acids 2012;1:e15.
  • 11
    Reebye V, Saetrom P, Mintz PJ, Rossi JJ, Kasahara N, Nteliopoulos G, et al. A short-activating RNA oligonucleotide targeting the islet β-cell transcriptional factor MafA in CD34(+) cells. Mol Ther Nucleic Acids 2013;2:e97.
  • 12
    Lekstrom-Himes J, Xanthopoulos KG. Biological role of the CCAAT/enhancer-binding protein family of transcription factors. J Biol Chem 1998;273:2854528548.
  • 13
    Umek RM, Friedman AD, McKnight SL. CCAAT-enhancer binding protein: a component of a differentiation switch. Science 1991;251:288292.
  • 14
    Timchenko NA, Wilde M, Nakanishi M, Smith JR, Darlington GJ. CCAAT/enhancer-binding protein alpha (C/EBP alpha) inhibits cell proliferation through the p21 (WAF-1/CIP-1/SDI-1) protein. Genes Dev 1996;10:804815.
  • 15
    Wang H, Iakova P, Wilde M, Welm A, Goode T, Roesler WJ, et al. C/EBPalpha arrests cell proliferation through direct inhibition of Cdk2 and Cdk4. Mol Cell 2001;8:817828.
  • 16
    Nerlov CC, Ziff EBE. Three levels of functional interaction determine the activity of CCAAT/enhancer binding protein-alpha on the serum albumin promoter. Genes Dev 1994;8:350362.
  • 17
    Poli VV, Mancini FPF, Cortese RR. IL-6DBP, a nuclear protein involved in interleukin-6 signal transduction, defines a new family of leucine zipper proteins related to C/EBP. Cell 1990;63:643653.
  • 18
    Wang ND, Finegold MJ, Bradley A, Ou CN, Abdelsayed SV, Wilde MD, et al. Impaired energy homeostasis in C/EBP alpha knockout mice. Science 1995;269:11081112.
  • 19
    Kimura T, Christoffels VM, Chowdhury S, Iwase K, Matsuzaki H, Mori M, et al. Hypoglycemia-associated hyperammonemia caused by impaired expression of ornithine cycle enzyme genes in C/EBPalpha knockout mice. J Biol Chem 1998;273:2750527510.
  • 20
    Ray A, Ray BK. Serum amyloid A gene expression under acute-phase conditions involves participation of inducible C/EBP-beta and C/EBP-delta and their activation by phosphorylation. Mol Cell Biol 1994;14:43244332.
  • 21
    Zhou J, Neff CP, Liu X, Zhang J, Li H, Smith DD, et al. Systemic administration of combinatorial dsiRNAs via nanoparticles efficiently suppresses HIV-1 infection in humanized mice. Mol Ther 2011;19:22282238.
  • 22
    Javitt NB. Hep G2 cells as a resource for metabolic studies: lipoprotein, cholesterol, and bile acids. The FASEB Journal 1990;4:161168.
  • 23
    Huang K-W, Huang YC, Tai KF, Chen BH, Lee PH, Hwang LH, et al. Dual therapeutic effects of interferon-α gene therapy in a rat hepatocellular carcinoma model with liver cirrhosis. Mol Ther 2008;16:16811687.
  • 24
    Zhou J, Wu J, Hafdi N, Behr JP, Erbacher P, Peng L. PAMAM dendrimers for efficient siRNA delivery and potent gene silencing. Chem Commun 2006;14:23622364.
  • 25
    Liu X, Liu C, Laurini E, Posocco P, Pricl S, Qu F, et al. Efficient delivery of sticky siRNA and potent gene silencing in a prostate cancer model using a generation 5 triethanolamine-core PAMAM dendrimer. Mol Pharmaceutics 2012;9:470481.
  • 26
    Semenkova LN, Dudich EI, Dudich IV. Induction of apoptosis in human hepatoma cells by alpha-fetoprotein. Tumor Biol 1997;18:261273.
  • 27
    Wang H, Iakova P, Wilde M, Welm A, Goode T, Roesler WJ, et al. C/EBPalpha arrests cell proliferation through direct inhibition of Cdk2 and Cdk4. Mol Cell 2001;8:817828.
  • 28
    Tatematsu MM, Mera Y, Inoue T, Satoh K, Sato K, Ito N. Stable phenotypic expression of glutathione S-transferase placental type and unstable phenotypic expression of gamma-glutamyltransferase in rat liver preneoplastic and neoplastic lesions. Carcinogenesis 1988;9:215220.
  • 29
    Harrison DJ, May L, Hayes JD, Neal GE. Glutathione S-transferase localization in aflatoxin B1-treated rat livers. Carcinogenesis 1990;11:927931.
  • 30
    Currier AR, Sabla G, Locaputo S, Melin_Aldana H, Degen JL, Bezerra JA. Plasminogen directs the pleiotropic effects of uPA in liver injury and repair. Am J Physiol Gastrointest Liver Physiol 2003;284:G508G515.
  • 31
    Song G, Chen G, Yun JP, Lai P. Association of p53 with bid induces cell death in response to etoposide treatment in hepatocellular carcinoma. Curr Cancer Drug Targets 2009;9:871880.
  • 32
    Oltvai ZN, Milliman CL, Korsmeyer SJ. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 1993;74:609619.
  • 33
    Seewoo V, Yang W, Du H, Wang J, Lin A, Shen B, et al. The different induction mechanisms of growth arrest DNA damage inducible gene 45 β in human hepatoma cell lines. Chemotherapy 2012;58:165174.
  • 34
    Kim TY, Lee JW, Kim HP, Jong HS, Kim TY, Jung M, et al. DLC-1, a GTPase-activating protein for Rho, is associated with cell proliferation, morphology, and migration in human hepatocellular carcinoma. Biochem Biophys Res Commun 2007;355:7277.
  • 35
    Shiraha H, Nishina S-I, Yamamoto K. Loss of runt-related transcription factor 3 causes development and progression of hepatocellular carcinoma. J Cell Biochem 2011;112:745749.
  • 36
    Tanaka S, Shiraha H, Nakanishi Y, Nishina S, Matsubara M, Horiguchi S, et al. Runt-related transcription factor 3 reverses epithelial-mesenchymal transition in hepatocellular carcinoma. Int J Cancer 2012;131:25372546.
  • 37
    Wu W-Y, Li J, Wu ZS, Zhang CL, Meng XL, Lobie PE. Prognostic significance of phosphorylated signal transducer and activator of transcription 3 and suppressor of cytokine signaling 3 expression in hepatocellular carcinoma. Exp Ther Med 2011;2:647653.
  • 38
    Wei R-C, Cao X, Gui JH, Zhou XM, Zhong D, Yan QL, et al. Augmenting the antitumor effect of TRAIL by SOCS3 with double-regulated replicating oncolytic adenovirus in hepatocellular carcinoma. Hum Gene Ther 2011;22:11091119.
  • 39
    Hatziapostolou M, Polytarchou C, Aggelidou E, Drakaki A, Poultsides GA, Jaeger SA, et al. An HNF4α-miRNA inflammatory feedback circuit regulates hepatocellular oncogenesis. Cell 2011;147:12331247.
  • 40
    Tan EH, Ma FJ, Gopinadhan S, Sakban RB, Wang N-D. C/EBPα knock-in hepatocytes exhibit increased albumin secretion and urea production. Cell Tissue Res 2007;330:427435.
  • 41
    Tomizawa M, Watanabe K, Saisho H, Nakagawara A, Tagawa M. Down-regulated expression of the CCAAT/enhancer binding protein alpha and beta genes in human hepatocellular carcinoma: a possible prognostic marker. Anticancer Res 2003;23:351354.
  • 42
    Mischoulon D, Rana B, Bucher NL, Farmer SR. Growth-dependent inhibition of CCAAT enhancer-binding protein (C/EBP alpha) gene expression during hepatocyte proliferation in the regenerating liver and in culture. Mol Cell Biol 1992;12:25532560.
  • 43
    Meng F, Henson R, Lang M, Wehbe H, Maheshwari S, Mendell JT, et al. Involvement of human micro-RNA in growth and response to chemotherapy in human cholangiocarcinoma cell lines. Gastroenterology 2006;130:21132129.
  • 44
    Ding X, Yang LY, Huang GW, Wang W, Lu W-Q. ADAM17 mRNA expression and pathological features of hepatocellular carcinoma. World J Gastrenterol 2004;10:27352739.
  • 45
    Kutay H, Bai S, Datta J, Motiwala T, Pogribny I, Frankel W, et al. Downregulation of miR-122 in the rodent and human hepatocellular carcinomas. J Cell Biochem 2006;99:671678.
  • 46
    Mochizuki S, Okada Y. ADAMs in cancer cell proliferation and progression. Cancer Sci 2007;98:621628.
  • 47
    He G, Yu GY, Temkin V, Ogata H, Kuntzen C, Sakurai T, et al. Hepatocyte IKKbeta/NF-kappaB inhibits tumor promotion and progression by preventing oxidative stress-driven STAT3 activation. Cancer Cell 2010;17:286297.
  • 48
    Shachaf CM, Kopelman AM, Arvanitis C, Karlsson A, Beer S, Mandl S, et al. MYC inactivation uncovers pluripotent differentiation and tumor dormancy in hepatocellular cancer. Nature 2004;431:11121117.
  • 49
    Wörns MA, Koch S, Niederle IM, Marquardt JU, Nguyen_Tat M, Gamstätter T, et al. The impact of patient and tumor baseline characteristics on the overall survival of patients with advanced hepatocellular carcinoma treated with sorafenib. Dig Liver Dis 2013;45:408413.
  • 50
    Carr BI. Some new approaches to the management of hepatocellular carcinoma. Semin Oncol 2012;39:369373.